FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| TBP-PI-HBr | Urinary Tract Infection | PHASE3 | COMPLETED |
| Dummy Infusion | Urinary Tract Infection | PHASE3 | COMPLETED |
| Dummy Tablets | Complicated Urinary Tract Infection | PHASE3 | COMPLETED |
| Ertapenem | Complicated Urinary Tract Infection | PHASE3 | COMPLETED |
| TBPM-PI-HBr | Complicated Urinary Tract Infection | PHASE3 | COMPLETED |
| Imipenem-cilastatin | Urinary Tract Infection | PHASE3 | COMPLETED |
| SPR720 500 mg | Nontuberculous Mycobacterial Pulmonary Disease (NT | PHASE2 | COMPLETED |
| SPR720 1000 mg | Nontuberculous Mycobacterial Pulmonary Disease (NT | PHASE2 | COMPLETED |
| SPR720 | Mycobacterium Avium Complex | PHASE2 | TERMINATED |
| Open-label Standard of Care | Mycobacterium Avium Complex | PHASE2 | TERMINATED |
SPRO holds $50.8M in cash and its operations are currently cash-flow neutral or positive. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for SPRO free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-08-06 | Zack Debra |
Purchase | $0 |
| 2026-08-06 | Zack Debra |
Purchase | $0 |
| 2026-06-25 | THOMAS FRANK E |
Purchase | $0 |
| 2026-06-25 | THOMAS FRANK E |
Purchase | $0 |
| 2026-06-25 | Pottage John C Jr |
Purchase | $0 |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for SPRO and 2 more tickers of your choice.
Create Free Account →